研究者業績
基本情報
- 所属
- 藤田医科大学 医学部 医学科 小児科学 教授
- 学位
- 臓器移植後のhuman herpesvirus 6(藤田保健衛生大学)
- J-GLOBAL ID
- 200901031230982717
- researchmap会員ID
- 5000044021
小児のウイルス感染症、特にヘルペスウイルスとロタウイルス感染を研究しています。
研究分野
1論文
466-
The Pediatric infectious disease journal 44(10) 937-941 2025年10月1日BACKGROUND: Kawasaki disease (KD) onset has been suggested to be associated with infections and various environmental factors. However, research on whether the delivery type plays a role in KD development is limited. This study investigated whether cesarean section (CS) or vaginal delivery (VD) is associated with KD onset using a large administrative claims database in Japan. METHOD: We conducted a case-control study using the JMDC Claims Database from January 2005 to December 2021. Data on children born via CS or VD and their mothers were collected. KD patients were identified from the source population, and controls without KD were randomly selected based on sex, age and registration time, each matched to 4 controls using a risk-set sampling technique. We analyzed the association between delivery type and KD onset using multivariate conditional logistic regression, defining KD as the primary outcome based on specific criteria. RESULTS: Case-control matching created 3363 pairs of cases (n = 3363) and controls (n = 13,363). The proportions of CS, maternal age, Charlson Comorbidity Index, presence of older siblings and low birth weight infants were significantly different between the cases and controls. In the multivariate analysis, KD onset was associated with CS [odds ratio (OR): 1.12; 95% confidence interval (CI): 1.02-1.24], the presence of older siblings (OR: 1.11; 95% CI: 1.02-1.21), lower birth weight (1001-2500 g) (OR: 1.22; 95% CI: 1.04-1.43) and antibiotic use (OR: 1.12; 95% CI: 1.02-1.24). CONCLUSIONS: The risk of developing KD may be influenced by the delivery type (CS or VD), the presence of older siblings, low birth weight and antibiotic use.
-
Journal of virology 99(9) e0105425 2025年9月23日Human herpesviruses 6A and 6B (HHV-6A/B) can integrate into the germline, resulting in inherited viral DNA-now proposed to be called "endogenous HHV-6A/B (eHHV-6A/B)." Present in 0.2-3% of humans, this integrated DNA is passed to offspring and may reactivate, posing health risks such as angina or lupus. To reduce confusion caused by varied terminology, researchers advocate using "eHHV-6A/B" for inherited forms and reserving "chromosomally integrated" for somatic integrations only.
-
Journal of medical virology 97(9) e70602 2025年9月The 12th International Conference on Human Herpesvirus (HHV)-6A, HHV-6B, and HHV-7 was held in Himeji, Japan, from March 25 to March 27, 2025. It attracted over 120 basic, translational, and clinical scientists from 17 countries. Important new information was presented regarding: studies of viral genes and proteins; mechanism of chromosomal integration of the viral genome; host cell interactions; inherited chromosomally integrated HHV-6A/B, also called endogenous HHV-6A/B); the role of the viruses in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS); the role of the viruses as opportunistic pathogens in immunocompromised people; the role of the viruses in diseases of the central nervous system, particularly encephalopathy, post-COVID neurological conditions, complex febrile seizures, and synucleinopathies; and the possible role of the viruses in non-Hodgkin lymphoma and autoimmune diseases, including systemic lupus erythematosus. In this review, we summarize many of the oral presentations. The full text of the Conference Abstracts is available at: https://hhv-6foundation.org/wp-content/uploads/2025/06/Abstracts_FINAL-3.10.25.pdf.
-
The Journal of dermatology 2025年8月19日
-
Journal of the Pediatric Infectious Diseases Society 14(7) 2025年8月7日BACKGROUND: Pediatric acute hepatitis of unknown etiology (AHUE) has been reported globally since April 2022. The purpose of the present study was to investigate the impact of coronavirus disease 2019 (COVID-19) pandemic on the incidence of AHUE in Japan. METHODS: A nationwide survey of AHUE was conducted in 2510 pediatric hospitals by the Japan Pediatric Society. We retrospectively reviewed AHUE cases, defined by the World Health Organization's working case definition, and compared the incidence, clinical characteristics, and causative pathogens before the COVID-19 pandemic period (pre-pandemic, January 2017 to December 2019) and during the pandemic period (pandemic, January 2020 to June 2022). RESULTS: In total, 707 cases (450 pre-pandemic, 257 pandemic) were reported. The median age was 3 years (interquartile range (IQR): 1-9 years), and 43.8% were female. The number of AHUE cases decreased significantly in the pandemic period (102.8 cases/year) compared with the pre-pandemic period (150.0 cases/year). Investigations of pathogens causing AHUE demonstrated that the most common cause was unknown, accounting for 64% and 75% of cases in the pre-pandemic and pandemic periods, respectively. Among those whose pathogens were identified, the most common pathogens were Epstein-Barr virus (9.6%), cytomegalovirus (6.2%), and influenza (4.0%) in the pre-pandemic, and 7.0%, 3.5%, and 0.4%, respectively, in the pandemic period. SARS-CoV-2 and adenovirus were only 2.7% and 1.9%, respectively, in the pandemic period. CONCLUSIONS: The number of AHUE cases decreased during the COVID-19 pandemic compared with the pre-pandemic period, and no increase in adenovirus-associated disease or severe cases was observed in Japan.
MISC
342-
JOURNAL OF VIROLOGICAL METHODS 193(2) 308-313 2013年11月 査読有り
-
日本小児科学会雑誌 117(9) 1416-1423 2013年9月1日第1期(1歳)にMRワクチンと水痘ワクチンを同時接種した82名、水痘ワクチンを単独接種した43名、MRワクチンを単独接種した51名を対象に、接種前後の水痘、麻疹、風疹のウイルス抗体価を測定し、副反応を調査した。同時接種者には水痘抗原に対するELISPOTアッセイを実施すると共に、接種1年後に水痘罹患状況を調査し、未罹患者に水痘ワクチンを追加接種した。更に、同時接種者には第2期(小学校就学前)にも再び同時接種し、ウイルス抗体価を測定した。その結果、水痘、麻疹、風疹ともに抗体陽転率および平均抗体価は単独接種群と同時接種群間で有意差はなかった。水痘特異的細胞性免疫能の評価では、71.4%に細胞性免疫が獲得されていた。同時接種から1年間の水痘罹患率は11%で、未罹患者に対し接種1年後に水痘ワクチンを追加接種したところブースター効果が認められた。第2期の同時接種後も、接種前と比べ水痘抗体価の有意な上昇がみられた。特に問題となる副反応はなかった。
-
日本臨床 別冊(感染症症候群(上)) 360-363 2013年7月
-
Brain and Development 35(6) 590-595 2013年6月 査読有り
-
Pediatric Blood & Cancer 60 326-328 2013年 査読有り
-
BMJ Case Reports 2013年 査読有り
-
PEDIATRIC INFECTIOUS DISEASE JOURNAL 31(11) 1202-1203 2012年11月 査読有り
-
BONE MARROW TRANSPLANTATION 47(10) 1381-1382 2012年10月 査読有り
-
International Journal of Hematology 96(4) 516-520 2012年10月 査読有り
-
JOURNAL OF MEDICAL VIROLOGY 84(9) 1388-1395 2012年9月 査読有り
-
MICROBIOLOGY AND IMMUNOLOGY 56(9) 651-655 2012年9月 査読有り
-
JOURNAL OF CLINICAL MICROBIOLOGY 50(4) 1245-1251 2012年4月 査読有り
-
TRANSPLANT INFECTIOUS DISEASE 14(1) 49-56 2012年2月 査読有り
-
J Med Virol 84 986-991 2012年 査読有り
-
Neuroinfection 16(2) 162-162 2011年10月21日
書籍等出版物
9講演・口頭発表等
17共同研究・競争的資金等の研究課題
29-
日本学術振興会 科学研究費助成事業 2024年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2021年4月 - 2024年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2021年4月 - 2024年3月
-
国立研究開発法人日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業 2022年4月 - 2024年3月